CHUGAI PHARMACEUTICAL CO., LTD. (4519) Stock Price

Chugai Pharmaceutical is a company primarily engaged in the pharmaceutical business. In Japan, it sells pharmaceuticals manufactured in-house through authorized distributors nationwide. Some manufacturing uses raw materials purchased from F. Hoffmann-La Roche Ltd. in Switzerland, and manufacturing is also outsourced to Chugai Pharma Manufacturing and Genentech in the United States. Research operations are outsourced to the Chugai Institute for Medical Science, and clinical development is handled by the Chugai Clinical Research Center.

In overseas operations, Chugai Pharma Europe Limited serves as the sales control company in Europe. F. Hoffmann-La Roche imports and sells certain products. Local subsidiaries in the United Kingdom, France, Germany, and other countries conduct sales activities. In Asia, Chugai Pharma Taiwan Co., Ltd. and Nichi-Ken Chugai Pharma Ltd. handle pharmaceutical sales.

Research and development activities are conducted by Chugai Pharma U.S.A., Inc. in the United States, Chugai Pharma Europe Limited in the United Kingdom, Nichi-Ken Chugai Pharma Ltd. in China, and Chugai Pharma Taiwan Co., Ltd. Chugai Pharma Body Research Pte. Ltd. in Singapore conducts research. Additionally, Chugai Venture Fund LLC in the United States engages in investment activities in startups.

Chugai Pharmaceutical has established its growth strategy "TOP I 2030" toward 2030, aiming to contribute to global healthcare through the creation of innovative medicines. This strategy targets achieving world-class drug discovery capabilities and realizing patient-centric, sustainable healthcare.

Chugai Pharmaceutical leverages its strategic alliance with Roche, focusing on innovation in drug discovery based on its proprietary scientific and technological capabilities. In particular, the company aims for long-term growth by doubling R&D output and launching its own global products annually.

"TOP I 2030" commits to reforming each value chain element—drug discovery, development, manufacturing, and Value Delivery—to strengthen the growth foundation. This aims to accelerate medicine development speed and maximize value for patients.

Chugai Pharmaceutical is advancing process restructuring through digital technology and building advanced business models responsive to environmental changes. These efforts target improved productivity across the entire value chain and the realization of sustainable healthcare.

As part of its growth foundation reform, the company is prioritizing human resource development, digitalization, and sustainability initiatives. This strengthens the company-wide foundation supporting innovation and contributes to addressing social challenges.